Outcomes of respiratory syncytial virus immunoprophylaxis in infants using an abbreviated dosing regimen of palivizumab

JAMA Pediatrics

Volumn 170, Issue 2, 2016, Pages 174-176

  Lavoie, Pascal M ^a,b   Solimano, Alfonso ^a   Taylor, Richard ^c   Kwan, Eddie ^a   Claydon, Jennifer ^a   Turvey, Stuart E ^a,b   Marr, Nico ^a,d,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF VICTORIA   (Canada)

^d Canadian Center for Vaccinology Dalhousie University Halifax   (Canada)

^e SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PALIVIZUMAB; ANTIVIRUS AGENT;

ANTIBODY TITER; BLOOD SAMPLING; CHILD HOSPITALIZATION; COHORT ANALYSIS; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; ICD-10; ICD-10-CM; IMMUNOPROPHYLAXIS; INFANT DISEASE; INNATE IMMUNITY; INTENTION TO TREAT ANALYSIS; LETTER; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRAL BRONCHIOLITIS; VIRAL RESPIRATORY TRACT INFECTION; VIRUS REPLICATION; IMMUNOLOGY; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ANTIVIRAL AGENTS; HUMANS; INFANT; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84956902971     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2015.3235     Document Type: Letter

References (6)

1. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176(5):1215-1224.
2. Brady MT; American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415-420.
3. Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr. 2015;169(4):341-348.
4. Weinberger DM, Warren JL, Steiner CA, Charu V, Viboud C, Pitzer VE. Reduced-dose schedule of prophylaxis based on local data provides near-optimal protection against respiratory syncytial virus. Clin Infect Dis. 2015; 61(4):506-514.
5. Mitchell I, Paes BA, Li A, Lanct KL; CARESS investigators. CARESS: The Canadian Registry of Palivizumab. Pediatr Infect Dis J. 2011;30(8):651-655.
6. Luchsinger V, Piedra PA, Ruiz M, et al. Role of neutralizing antibodies in adults with community-Acquired pneumonia by respiratory syncytial virus. Clin Infect Dis. 2012;54(7):905-912.